Your SlideShare is downloading. ×
Hepatitis E infection
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Hepatitis E infection

2,502

Published on

Hepatitis E infection

Hepatitis E infection

Published in: Health & Medicine
2 Comments
3 Likes
Statistics
Notes
No Downloads
Views
Total Views
2,502
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
201
Comments
2
Likes
3
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. HEPATITIS E INFECTION Dr.T.V.Rao MDDR.T.V.RAO MD 1
  • 2. WHAT IS VIRAL HEPATITIS E• Hepatitis E is a viral hepatitis caused by infection with a virus called hepatitis E virus (HEV). HEV is a positive-sense single-stranded RNA icosahedral virus with a 7.5 kilobase genome. HEV has a fecal-oral transmission route. It is one of five known hepatitis viruses: A, B, C, D, and E. Infection with this virus was first documented in 1955 during an outbreak in New Delhi, IndiaDR.T.V.RAO MD 2
  • 3. A TRUE STORY OF HEPATITIS E INFECTION• In 1983, Dr. Balayan was investigating an outbreak of non-A, non-B hepatitis in a central Asian part of the Soviet Union. Though he wanted to bring samples back to his Moscow laboratory, he lacked refrigeration. So he made a shake of yogurt and an infected patient’s stool, drank it, went back to Moscow, and waited. When he became seriously ill a few weeks later, he started collecting and analysing his own samples. In these he found a new virus that produced liver injury in laboratory animals and could be seen by electron microscopy. It looked a lot like hepatitis A virus, but he could show that it was not, because he already had antibodies against the hepatitis A virus and these did not react with the new virus.• ( National Institute of Allergy and Infectious Diseases )DR.T.V.RAO MD 3
  • 4. ROBERT PURCELL, ALBERT KAPIKIAN, AND STEPHEN FEINSTONE WITH AN ELECTRON MICROSCOPE. (CREDIT: NIAID) DR.T.V.RAO MD 4
  • 5. HEPATITIS E - GENOME• The genome is approximately 7200 bases in length, is a polyadenylated single-strand RNA molecule that contains three discontinuous and partially overlapping open reading frames (ORFs) along with 5 and 3 cis-acting elements, which have important roles in HEV replication and transcription. ORF1 encode a methyltransferase, protease, helicase and replicase; ORF2 encode the capsid protein and ORF3 encodes a protein of undefined function. A three-dimensional, atomic-resolution structure of the capsid protein in the context of a virus-like particle has been described. An in vitro culture system is not yet available DR.T.V.RAO MD 5
  • 6. Hepatitis E - Clinical Features  Incubation period: Average 40 days Range 15-60 days  Case-fatality rate: Overall, 1%-3% Pregnant women, 15%-25%  Illness severity: Increased with age  Chronic sequelae: None identifiedDR.T.V.RAO MD 6
  • 7. Hepatitis E Epidemiologic Features  Most outbreaks associated with faecally contaminated drinking water.  Several other large epidemics have occurred since in the Indian subcontinent and the USSR, China, Africa and Mexico.  In the United States and other nonendemic areas, where outbreaks of hepatitis E have not been documented to occur, a low prevalence of anti-HEV (<2%) has been found in healthy populations. The source of infection for these persons is unknown.  Minimal person-to-person transmission.DR.T.V.RAO MD 7
  • 8. GEOGRAPHICAL DISTRIBUTION• Hepatitis E is found worldwide and different genotypes of the hepatitis E virus determine differences in epidemiology. For example, genotype 1 is usually seen in developing countries and causes community level outbreaks while genotype 3 is usually seen in the developed countries and does not cause outbreaksDR.T.V.RAO MD 8
  • 9. DR.T.V.RAO MD 9
  • 10. DISTRIBUTION OF HEPATITIS E INFECTION, 2010DR.T.V.RAO MD 10
  • 11. MORBIDITY AND MORTALITY• Globally, 70 000 deaths and 3.4 million cases of acute hepatitis E are attributable to infection with hepatitis E virus genotypes 1 and 2.DR.T.V.RAO MD 11
  • 12. TRANSMISSION OF INFECTION• The hepatitis E virus is transmitted mainly through the faecal- oral route due to faecal contamination of drinking water. Other transmission routes have been identified, which includeDR.T.V.RAO MD 12
  • 13. DR.T.V.RAO MD 13
  • 14. Prevention and Control Measures for Travelers to HEV-Endemic Regions  Avoid drinking water (and beverages with ice) of unknown purity, uncooked shellfish, and uncooked fruit/vegetables not peeled or prepared by traveler.  IG prepared from donors in Western countries does not prevent infection.  Unknown efficacy of IG prepared from donors in endemic areas.  Vaccine?DR.T.V.RAO MD 14
  • 15. TRANSMISSION• Foodborne transmission from ingestion of products derived from infected animals;• Zoonotic transmission from animals to humans;• Transfusion of infected blood products;• Vertical transmission from a pregnant woman to her foetus.DR.T.V.RAO MD 15
  • 16. INCUBATION PERIOD• The incubation period following exposure to the hepatitis E virus ranges from three to eight weeks, with a mean of 40 days. The period of communicability is unknown.DR.T.V.RAO MD 16
  • 17. SYMPTOMS• The hepatitis E virus causes acute sporadic and epidemic viral hepatitis. Symptomatic infection is most common in young adults aged 15–40 years. Although infection is frequent in children, the disease is mostly asymptomatic or causes a very mild illness without jaundice (anicteric) that goes undiagnosedDR.T.V.RAO MD 17
  • 18. CLINICAL PRESENTATIONJaundice• anorexia (loss of appetite);• an enlarged, tender liver (hepatomegaly);• abdominal pain and tenderness;• nausea and vomiting;• fever.DR.T.V.RAO MD 18
  • 19. HEPATITIS E INFECTION AND PREGNANCY• In rare cases, acute hepatitis E can result in fulminant hepatitis (acute liver failure) and death. Overall population mortality rates from hepatitis E range from 0.5% to 4.0%. Fulminant hepatitis occurs more frequently during pregnancy. Pregnant women are at greater risk of obstetrical complications and mortality from hepatitis E, which can induce a mortality rate of 20% among pregnant women in their third trimester.DR.T.V.RAO MD 19
  • 20. CHRONIC HEPATITIS E INFECTION• Cases of chronic hepatitis E infection have been reported in immunosuppressed people. Reactivation of hepatitis E infection has also been reported in immunocompromised people.DR.T.V.RAO MD 20
  • 21. DIAGNOSIS BY DETECTION OF ANTIBODIES • Diagnosis of hepatitis E infection is therefore usually based on the detection of specific antibodies to the virus in theDR.T.V.RAO MD blood. 21
  • 22. NEWER METHODS IN DIAGNOSIS• Reverse transcriptase polymerase chain reaction (RT-PCR) to detect the hepatitis E virus RNA;• Immune electron microscopy to detect the hepatitis E virus.DR.T.V.RAO MD 22
  • 23. TREATMENT• There is no available treatment capable of altering the course of acute hepatitis. Prevention is the most effective approach against the disease.• As hepatitis E is usually self-limiting, hospitalization is generally not required. However, hospitalization is required for people with fulminant hepatitis and should also be considered for infected pregnant women.DR.T.V.RAO MD 23
  • 24. PREVENTIONMaintaining qualitystandards for publicwater supplies ; Establishing properdisposal systems toeliminate sanitarywaste.DR.T.V.RAO MD 24
  • 25. PREVENTION• Maintaining hygienic practices such as hand washing with safe water, particularly before handling food;• Avoiding drinking water and/or ice of unknown purity;• Avoiding eating uncooked shellfish, and uncooked fruits or vegetables that are not peeled or that are prepared by people living in or travelling in highly endemic countriesDR.T.V.RAO MD 25
  • 26. VACCINATION - UPDATE• China has produced and licensed the first vaccine to prevent hepatitis E virus infection, although it is not yet available globally.DR.T.V.RAO MD 26
  • 27. • Programme Created by Dr.T.V.Rao MD for Medical and Paramedical Students in the Developing World • Email • doctortvrao@gmail.comDR.T.V.RAO MD 27

×